Research programme: neurodegenerative disorders therapeutics - Horizon Pharma/Roche

Drug Profile

Research programme: neurodegenerative disorders therapeutics - Horizon Pharma/Roche

Latest Information Update: 14 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Developer Raptor Pharmaceutical Corp; Roche
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Neurodegenerative disorders

Most Recent Events

  • 12 Aug 2014 No development reported - Preclinical for Neurodegenerative disorders in USA (IV)
  • 30 Sep 2009 TorreyPines Therapeutics Inc has merged with Raptor Pharmaceuticals Corp to form Raptor Pharmaceutical Corp
  • 09 Jun 2009 Preclinical trials in Neurodegenerative disorders in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top